<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/fulgent-genetics-inc-logo-1200x675.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/fulgent-genetics-inc-logo-1200x675.jpg"/>Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 1,075 shares of the firm's stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total transaction of $30,454.75. Following the transaction, the insider directly owned 952,890 shares in the company, valued at approximately $26,995,373.70. The trade was a 0.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.</p><ul><li>Can Fulgent Sustain Sky-High Growth Post-Pandemic? </li></ul><p>Hanlin Gao also recently made the following trade(s): </p><ul><li>On Friday, November 28th, Hanlin Gao sold 943 shares of Fulgent Genetics stock. The stock was sold at an average price of $29.57, for a total transaction of $27,884.51. </li><li>On Monday, November 24th, Hanlin Gao sold 535 shares of Fulgent Genetics stock. The shares were sold at an average price of $30.47, for a total transaction of $16,301.45. </li></ul><h2>Fulgent Genetics Price Performance</h2><p>Shares of NASDAQ:FLGT opened at $28.55 on Thursday. The stock has a market cap of $882.57 million, a price-to-earnings ratio of -20.45 and a beta of 0.64. Fulgent Genetics, Inc. has a 12 month low of $14.57 and a 12 month high of $31.04. The stock's 50 day moving average price is $25.24 and its 200 day moving average price is $22.17. </p><hr/><hr/><p>Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last issued its quarterly earnings results on Friday, November 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.36. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%.The company had revenue of $84.07 million for the quarter, compared to analysts' expectations of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS.  On average, sell-side analysts expect that  Fulgent Genetics, Inc. will post -0.85 EPS for the current year. </p><h2>Institutional Trading of Fulgent Genetics</h2><p>A number of institutional investors have recently bought and sold shares of FLGT. Signaturefd LLC increased its position in  Fulgent Genetics by 60.4% in the 2nd quarter. Signaturefd LLC now owns 1,914 shares of the company's stock worth $38,000 after purchasing an additional 721 shares during the last quarter.  Raymond James Financial Inc. acquired a new stake in  Fulgent Genetics in the second quarter valued at approximately $49,000.  Quantbot Technologies LP bought a new stake in  Fulgent Genetics in the third quarter worth approximately $61,000.  PNC Financial Services Group Inc. increased its stake in shares of  Fulgent Genetics by 122.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,562 shares of the company's stock worth $60,000 after purchasing an additional 1,963 shares during the last quarter.  Finally, State of Wyoming raised its holdings in shares of  Fulgent Genetics by 111.1% during the 1st quarter. State of Wyoming now owns 6,564 shares of the company's stock valued at $111,000 after purchasing an additional 3,455 shares in the last quarter. Institutional investors and hedge funds own  48.06% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>FLGT has been the subject of several analyst reports. Wall Street Zen raised Fulgent Genetics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 15th. Raymond James Financial  reaffirmed an &#34;outperform&#34; rating and issued a $36.00 target price on shares of Fulgent Genetics in a research report on Friday, November 14th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Fulgent Genetics in a report on Wednesday, October 8th. Finally, Piper Sandler increased their price objective on Fulgent Genetics from $21.00 to $30.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat.com, the stock  has an average rating of &#34;Hold&#34; and an average target price of $32.00.</p><p><b>Read Our Latest Research Report on FLGT</b></p><h2>Fulgent Genetics Company Profile</h2><p> (Get Free Report)</p><p>Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.</p><h2>See Also</h2><ul><li>Five stocks we like better than Fulgent Genetics</li><li>Growth Stocks: What They Are, Examples and How to Invest</li><li>Battle of the Big-Upside Tech Names: HUBS vs. NBIS vs. TEAM</li><li>Procter &amp; Gamble (NYSE:PG) Pulls Back After Shaky Guidance</li><li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li><li>What Are Growth Stocks and Investing in Them </li><li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkxHVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkxHVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Fulgent Genetics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Fulgent Genetics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://20286994.fs1.hubspotusercontent-na1.net/hubfs/20286994/dollar%20burning.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1980" height="1119" original-src="https://imageproxy.pbkrs.com/https://20286994.fs1.hubspotusercontent-na1.net/hubfs/20286994/dollar%20burning.png"/></p><div><p>What I'm about to show you will make your stomach drop...</p><p>The question is: How much more are you willing to lose before you do something about it?</p><p><span>National Gold Group</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4Nw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250609131037_pushelonnew-6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250609131037_pushelonnew-6.jpg"/></p><div><p>Nvidia CEO Issues Bold Tesla Call</p><p>While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251117133757_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251117133757_pushgold-bullion-163553640.jpg"/></p><div><p>BRICS Push to Kill Dollar—Gold Eyes $6,000 Next</p><p>Gold recently broke above $4,200 an ounce, and with analysts now calling for $6,000 under a Trump administrati...</p><p><span>Americas Gold Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIzNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIzNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/4f3bc4e2-image-1_10zg0si000000000000028.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1276" height="1026" original-src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/4f3bc4e2-image-1_10zg0si000000000000028.png"/></p><div><p>What a Former CIA Agent Knows About the Coming Collapse</p><p> This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...</p><p><span>Advantage Gold</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIzMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIzMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/iores/169207965eb0bb?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/iores/169207965eb0bb"/></p><div><p>With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026</p><p>Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-38...</p><p><span>Equiscreen</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU1MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU1MA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg"/></p><div><p>“$6.6 Trillion Of Customer Bank Deposits At Risk”</p><p>The Treasury Department just issued a stunning warning:  U.S. banks could lose up to $6.6 trillion of custom...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxNw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250904094329_pushtrumpnew-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250904094329_pushtrumpnew-3.jpg"/></p><div><p>REVEALED: Something Big Happening Behind White House Doors</p><p>What I just learned about what’s unfolding in the White House is truly stunning…  And you need to see it for...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/musk%20warning%201.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="245" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/musk%20warning%201.png"/></p><div><p>Elon Warns “America Is Broke”. Trump’s Plan Inside.</p><p>For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...</p><p><span>American Hartford Gold</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjMzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjMzOQ"/></p></div></div></div>                     </div>                 </div></div>

FLGT

<p>Fulgent Genetics insider Hanlin Gao sold 1,075 shares at $28.33 each, totaling $30,454.75. Post-sale, Gao owns 952,890 shares valued at $26,995,373.70, marking a 0.11% position decrease. Recent trades include selling 943 shares at $29.57 and 535 shares at $30.47. Fulgent's stock opened at $28.55, with a market cap of $882.57 million. Analysts have mixed ratings, with a target price of $32.00. Institutional investors hold 48.06% of shares.</p>

Insider Selling: Fulgent Genetics (NASDAQ:FLGT) Insider Sells 1,075 Shares of Stock